TY - JOUR T1 - Usefulness of Nanofluidic Digital PCR Arrays to Quantify T790M Mutation in <em>EGFR</em>-mutant Lung Adenocarcinoma JF - Cancer Genomics - Proteomics JO - Cancer Genomics Proteomics SP - 31 LP - 37 VL - 12 IS - 1 AU - KAZUTOSHI ISOBE AU - YOSHINOBU HATA AU - NAOBUMI TOCHIGI AU - KYOHEI KABURAKI AU - HIROSHI KOBAYASHI AU - TAKASHI MAKINO AU - HAJIME OTSUKA AU - FUMIAKI ISHIDA AU - NAO HIROTA AU - GO SANO AU - KEISHI SUGINO AU - SUSUMU SAKAMOTO AU - YUJIRO TAKAI AU - KAZUTOSHI SHIBUYA AU - AKIRA IYODA AU - SAKAE HOMMA Y1 - 2015/01/01 UR - http://cgp.iiarjournals.org/content/12/1/31.abstract N2 - Aim: The present pilot study assessed the usefulness of nanofluidic digital polymerase chain reaction (PCR) arrays in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma after tyrosine kinase inhibitor (TKI) resistance. Patients and Methods: We enrolled 12 patients with primary lung adenocarcinoma with sensitive EGFR mutation-confirmed T790M status by re-biopsy after TKI resistance. Nanofluidic digital PCR arrays were used to quantify T790M in genomic DNA from the pre-treatment primary site and in serum cell-free DNA (cfDNA). Results: On digital PCR, quantified T790M at the pre-treatment primary site was higher in re-biopsy-positive T790M patients (n=4) than in re-biopsy-negative patients (n=8) (0.78%±0.36% vs. 0.07%±0.09%, p&lt;0.01). T790M at the pre-treatment primary site correlated with progression-free survival (PFS) after gefitinib therapy (r=0.67, p=0.016). Conclusion: Use of digital PCR to quantify T790M at the primary site of EGFR-mutant lung adenocarcinoma predicted T790M emergence in re-biopsies after TKI resistance and PFS after gefitinib therapy. ER -